We are live on ! Find out more
SLNO

Soleno Therapeutics
SLNO

Delisted

SLNO was delisted on the 15th of May, 2026.

Back to rankings

17 hedge funds and large institutions have $22.2M invested in Soleno Therapeutics in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 1

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

89% more funds holding

Funds holding: 9 → 17 (+8)

35% more capital invested

Capital invested by funds: $16.4M → $22.2M (+$5.77M)

0.9% more ownership

Funds ownership: 47.03% → 47.93% (+0.9%)

Holders
17
Holders Change
+8
Holders Change %
+88.89%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
5
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$638K
2
TMC
Trellus Management Company
Florida
+$253K
3
OIM
Oracle Investment Management
Connecticut
+$97.7K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$86.7K
5
KC
Kepos Capital
New York
+$73.5K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$258K
2
DZ Bank
DZ Bank
Germany
-$215K

SLNO Hedge Fund Activity: Q2 2018 in Review

17 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q2 2018, worth a combined $22.2M — up 35% from $16.4M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new SLNO positions and 1 closed out — a net gain of 8 holders — while 5 added to existing stakes and 1 trimmed.

The largest buyer was Vivo Capital, adding an estimated $638K. The largest seller was Sabby Management, cutting an estimated $258K.

  • 17 institutional investors held Soleno Therapeutics (SLNO) as of Q2 2018, up from 9 in Q1 2018.
  • Funds reported $22.2M of Soleno Therapeutics stock for Q2 2018, up 35% quarter-over-quarter.
  • 9 funds opened new Soleno Therapeutics positions in Q2 2018 and 1 closed out, a net change of +8 holders.
  • The largest Soleno Therapeutics buyer in Q2 2018 was Vivo Capital, an estimated $638K added.
  • The largest Soleno Therapeutics seller in Q2 2018 was Sabby Management, an estimated $258K sold.

Based on aggregated 13F filings for Q2 2018.